for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Merrimack Pharmaceuticals Inc

MACK.OQ

Latest Trade

3.87USD

Change

0.00(0.00%)

Volume

10,933

Today's Range

3.83

 - 

3.94

52 Week Range

1.50

 - 

5.84

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
3.87
Open
3.90
Volume
10,933
3M AVG Volume
0.91
Today's High
3.94
Today's Low
3.83
52 Week High
5.84
52 Week Low
1.50
Shares Out (MIL)
13.38
Market Cap (MIL)
51.78
Forward P/E
--
Dividend (Yield %)
--

Next Event

Q3 2020 Merrimack Pharmaceuticals Inc Earnings Release

Latest Developments

More

Merrimack Reports Q2 Loss Per Share Of $0.09

Merrimack Reports First Quarter 2020 Financial Results

Replimune Appoints Jean Franchi As Chief Financial Officer

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Merrimack Pharmaceuticals Inc

Merrimack Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in designing novel treatments for cancer by targeting biomarker-defined cancers. Its clinical programs include MM-121 (seribantumab), MM-141 (istiratumab) and MM-310. MM-121 is a fully human monoclonal antibody that binds to the ErbB3 (HER3) receptor and targets heregulin positive cancers. MM-141 is a fully human tetravalent bispecific antibody designed to block tumor survival signals by targeting receptor complexes containing the insulin-like growth factor 1, or IGF-1, receptor and ErbB3 (HER3) cell surface receptor. MM-310 is an antibody-directed nanotherapeutic that targets the ephrin receptor A2, or EphA2, receptor and contains a novel prodrug of the highly potent chemotherapy docetaxel. The Company’s preclinical programs include MM-161, ATRi, BCL2/BCLxl, TRAIL, Immuno-oncology and STIMULI.

Industry

Biotechnology & Drugs

Contact Info

1 Broadway Fl 14

CAMBRIDGE, MA

02142-1187

United States

+1.617.4411000

https://www.merrimack.com/

Executive Leadership

Gary L. Crocker

Chairman of the Board, President, Treasurer

Eric D. Andersen

Independent Director

Noah G. Levy

Independent Director

Ulrik B. Nielsen

Independent Director

Russell T. Ray

Independent Director

Key Stats

Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
2.99
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-7.98
Return on Equity (TTM)
-7.09

Latest News

Latest News

BRIEF-Merrimack Reports First Quarter 2020 Financial Results

* AS OF MARCH 31, HAD CASH AND CASH EQUIVALENTS AND INVESTMENTS OF $18.0 MILLION Source text for Eikon: Further company coverage:

BRIEF-Merrimack Divests Early Stage Asset For $2.25 Mln Provides Strategy Update

* MERRIMACK DIVESTS EARLY STAGE ASSET FOR $2.25 MILLION; PROVIDES STRATEGY UPDATE

BRIEF-Merrimack Pharmaceuticals Entered Into An Asset Purchase Agreement With Celator Pharmaceuticals, Inc.

* MERRIMACK PHARMACEUTICALS INC - ENTERED INTO AN ASSET PURCHASE AGREEMENT WITH CELATOR PHARMACEUTICALS, INC.

Ex-Merrimack Pharmaceuticals employee gets prison for insider trading

A former Merrimack Pharmaceuticals Inc employee was sentenced on Tuesday to six months in prison after being convicted of participating in an insider trading scheme with a friend at a rival biopharmaceutical company.

Merrimack to scrap development of pancreatic cancer treatment

Merrimack Pharmaceuticals Inc said on Monday it would stop developing its experimental treatment for pancreatic cancer after it failed to meet the main and secondary goals in a mid-stage trial.

Merrimack to scrap development of pancreatic cancer treatment

Merrimack Pharmaceuticals Inc said on Monday it would discontinue the development of an experimental treatment for pancreatic cancer after the drug failed to meet the main and secondary goals of a mid-stage trial.

BRIEF-Merrimack Pharmaceuticals Reports Q1 Operating Loss Per Share Of $1.33

* THREE CLINICAL READOUTS EXPECTED IN 2018, INCLUDING DATA FROM TWO RANDOMIZED PHASE 2 STUDIES

BRIEF-Merrimack Provides Business Update And Reports 2017 Financial Results

* MERRIMACK PROVIDES BUSINESS UPDATE AND REPORTS 2017 FINANCIAL RESULTS

BRIEF-Merrimack Strengthens SHERLOC Study Of MM-121 In Non-Small Cell Lung Cancer

* MERRIMACK STRENGTHENS SHERLOC STUDY OF MM-121 IN NON-SMALL CELL LUNG CANCER

BRIEF-Merrimack Says Dosed First Patient In Randomized Phase 2 Clinical Study Of MM-121

* MERRIMACK - DOSED FIRST PATIENT IN RANDOMIZED PHASE 2 CLINICAL STUDY OF MM-121 IN PATIENTS WITH POST-MENOPAUSAL METASTATIC BREAST CANCER

BRIEF-Merrimack Pharmaceuticals Files For Mixed Shelf Of Upto $150 Mln

* MERRIMACK PHARMACEUTICALS INC FILES FOR MIXED SHELF OF UPTO $150 MILLION - SEC FILING Source text :[http://bit.ly/2yGsbJv] Further company coverage:

BRIEF-Merrimack reports Q3 loss per share from continuing operations $0.40

* Merrimack Pharmaceuticals Inc - Qtrly loss per share from continuing operations $0.40

BRIEF-Merrimack receives orphan drug designation for MM-121 for the treatment of type of lung cancer

* Merrimack receives orphan drug designation for MM-121 for the treatment of heregulin positive non-small cell lung cancer

BRIEF-Merrimack commences tender offer for outstanding 4.50 pct convertible senior notes

* Merrimack commences tender offer for any and all of its outstanding 4.50 pct convertible senior notes due 2020

BRIEF-Merrimack announces settlement of convertible note litigation

* Merrimack announces settlement of convertible note litigation

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up